Xoma Ltd. deal

Xoma sold its rights to royalties for autoimmune drug Cimzia certolizumab pegol to an undisclosed party for $4 million. UCB Group (Euronext:UCB, Brussels, Belgium) markets the pegylated humanized antibody fragment against TNF alpha for Crohn's disease in the U.S. and for rheumatoid arthritis (RA) in the U.S. and EU. Cimzia is partnered with Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) in Japan and uses bacterial cell expression technology from Xoma. At June 30, Xoma received six-month royalties of $500,000 for Cimzia. ...